"progression free survival" trang 4 - tải miễn phí từ tailieunhanh
Long-term results of postoperative unsuspected small cell lung cancer on real-world data

Long-term results of postoperative unsuspected small cell lung cancer on real-world data
10    2    1
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma

The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
10    1    1
Development and validation of a prognostic nomogram model incorporating routine laboratory biomarkers for preoperative patients with endometrial cancer

Development and validation of a prognostic nomogram model incorporating routine laboratory biomarkers for preoperative patients with endometrial cancer
10    2    1
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
10    57    1
Báo cáo toán học:

Báo cáo toán học: "MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER"
6    62    0
báo cáo khoa học:

báo cáo khoa học: "RRM1 single nucleotide polymorphism -37C®A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy"
8    94    0
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
9    83    0
Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: A case report

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: A case report
4    80    0
Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma

Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
12    64    0
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
7    66    0
Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
9    81    1
Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer

Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer
11    42    1
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial
6    60    1
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
9    44    1
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
7    38    1
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial
8    54    1
Impact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancer

Impact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancer
13    69    1
MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
11    93    1
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
8    29    1
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
8    44    1